Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496039 · ClinicalTrials.gov registry record · Phase 4
Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)
A Phase 4 study, sponsored by Avanir Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT02496039 is a Phase 4 study that was terminated before completion, run by Avanir Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT02496039, a Phase 4 study, was terminated before completion, sponsored by Avanir Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
6 month study of NUEDEXTA ® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients.
Interventions
- DRUG NUEDEXTA®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02496039
The ClinicalTrials.gov registry entry for NCT02496039 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NUEDEXTA® is the first listed.
NCT02496039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02496039 about?
NCT02496039 is a clinical study titled "Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)". 6 month study of NUEDEXTA ® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients.
What is the current status of trial NCT02496039?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2015-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02496039?
The interventions under investigation include: NUEDEXTA® (DRUG).
Who is sponsoring clinical trial NCT02496039?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.